anti-TIF1γ Antibodies Research Articles

The diagnostic work-up of cancer-associated myositis.

Despite the well-recognized association between malignancy and myositis, definite data indicating the best strategy for diagnosing cancer in myositis patients is lacking. In this article, we review the data on cancer screening in patients with myositis, and propose an algorithm for this purpose based on recently published data. Evidence has recently emerged supporting blind screening in patients with certain myositis phenotypes. In addition to the clinical examination, imaging techniques such as PET/computed tomography scanning and whole-body MRI, and determination of the autoantibody profile beyond anti-TIF1γ antibody, the well known cancer biomarker in dermatomyositis, will help the clinician face this complex clinical situation. Molecules related to the checkpoint inhibitor pathway, specifically soluble programmed death 1, may also have a role in the diagnostic work-up of cancer in myositis. In the future, blood tests analysing circulating DNA will certainly help in detecting patients with cancer-associated myositis (CAM). A step forward has been achieved in the pathway to establish optimal cancer screening for myositis patients. International consensus guidelines for an effective diagnostic work-up of CAM are in progress and will be of paramount importance to improving the outcome in these patients.

521 DRB1 is the primary genetic locus contributing to susceptibility to dermatomyositis positive for anti-TIF1γ antibody in Japanese

521 DRB1 is the primary genetic locus contributing to susceptibility to dermatomyositis positive for anti-TIF1γ antibody in Japanese

Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.

An association between cancer and dermatomyositis (DM) is well recognized. The high frequency of malignancies detected close to DM diagnosis suggest that DM can be a paraneoplastic syndrome. Recently, anti-transcription intermediary factor 1γ (anti-TIF1γ) has been discovered to be associated with cancer and with DM. A meta-analysis reported the pooled sensitivity of anti-p155 for diagnosing cancer-associated DM to be 78% and the specificity to be 89%. Thus, anti-TIF1γ has shown promising results as a marker for cancer-associated DM. However, none of the studies evaluated the association of anti-TIF1γ with cancer with or without rheumatic diseases other than DM. To clarify the specificity of anti-TIF1γ antibodies as a biomarker for cancer-associated DM, we analyzed the frequency of anti-TIF1γ antibodies in other cancer-associated rheumatic syndromes, as well as in cancer patients and healthy controls. Sera from patients with paraneoplastic rheumatic syndrome (n = 91), patients with solid cancer (n = 95), and healthy controls (n = 80) were analyzed for the frequency of anti-TIF1γ IgG by enzyme-linked immunosorbent assay using a commercially available recombinant TIF1γ protein as coating antigen. The cutoff value was calculated by adding 2 SD to the mean optical density value of 80 healthy controls. The rate of anti-TIF1γ IgG positivity was 3.3% (n = 3) in patients with paraneoplastic rheumatic syndrome, 3.1% (n = 3) in cancer patients, and 1.3% (n = 1) in healthy controls. There were no significant differences in positivity between the groups (P < 0.05). Anti-TIF1γ antibodies are rarely present in patients with solid cancers or paraneoplastic rheumatic syndromes. This finding strengthens the approach to using anti-TIF1γ IgG as a marker for cancer-associated DM.

Intramuscular haemorrhage in a patient with dermatomyositis and anti-TIF1γ antibodies

Intramuscular haemorrhage in a patient with dermatomyositis and anti-TIF1γ antibodies

Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy.

The group of idiopathic inflammatory myopathies (IIM) include various disorders of skeletal muscles with or without skin involvement. The most common types are dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM). Dermatomyositis subdivides into various clinical forms such as juvenile, amyopathic or paraneoplastic dermatomyositis, scleromyositis, overlap or anti-synthetase syndromes, etc. Recently, numerous new antibodies defining the characteristic clinical phenotype have been described as anti-MDA5 antibodies associated with interstitial lung disease and amyopathic dermatomyositis or anti-TIF1γ antibodies as markers for paraneoplastic dermatomyositis. Moreover, new clinical entities as drug-induced dermatomyositis are presumed, since some medications may induce, or trigger inflammatory myopathies. Knowledge of the complex methods and techniques required to diagnose the disease is of great importance in clinical practice. The variety of clinical variants needs diagnosis because of the differing prognosis and therapeutic modalities.

Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum

Objective To explore the clinical and serological features of patients with pneumom-diastinum (PNM) and dermatomyositis associated interstitial lung disease (DM-ILD). Methods A total of 145 polymyositis/dermatomyositis (PM/DM) patients hospitalized in our department from March, 2010 to December, 2012 were recruited. The sera, clinical and laboratory data were collected. Anti-aminoacyl-tRNA synthetase (anti-ARS) and anti-melanoma differentiation-associated gene 5 (MDA5) antibodies were detected by RNA-immunoprecipitation (RNA-IP) and ELISA, respectively. Anti-NXP2, anti-TIF1γ, anti-SRP, anti-SAE and anti-Mi2 antibodies were detected by immunoprecipitation-Western blotting. Variables were compared between DM patients with and without PNM, as well as between DM-ILD patients with and without PNM. Chi square test, Fisher's exact test, t test, Mann-Whitney U test and a multivariate logistic regression model were used for statistical analysis. Results A total of 11 DM patients (10 patients positive for anti-MDA5 and 1 patient positive for anti-Mi2) developed spontaneous PNM. No PM patient developed PNM. No differences of sex, age at the onset of DM, serum ferritin levels and C reactive protein (CRP) levels was observed between DM patients with and without PNM. Compared with DM patients without PNM, DM patients with PNM had significantly higher frequencies of rapidly progressive ILD (RP-ILD) (63.6% vs 24.4%, χ2=7.25, P=0.01), anti-MDA5 antibodies (90.9% vs 52.4%, χ2=5.86, P=0.02), clinically amyopathic DM (CADM) (63.6% vs 22.0%, χ2=8.57, P=0.007) and cutaneous ulcers (36.4% vs 11%, χ2=5.20, P=0.04), but significantly lower creatine kinase (CK) levels [58.5 (30.5, 394.3) U/L vs 284 (73.0, 917.0) U/L, t=207.5, P=0.04]. The logistic multivariate analysis indicated that cutaneous ulcer was the only independent risk factor for the occurrence of PNM in DM [OR=5.98, 95% confidence interval (CI) (1.12, 31.98), P=0.037]. In the comparisons between DM-ILD patients with and without PNM, a higher frequency of CADM was observed in the PNM group (63.6% vs 27.9%, χ2=5.37, P=0.03), but no significant difference of the frequencies of RP-ILD, anti-MDA5 antibodies, cutaneous ulcers and CK levels was found in these two groups. All patients with PNM were treated with corticosteroids and immunosuppressants. During the follow-up period, 6 patients died of respiratory failure. Conclusion Spontaneous PNM is a refractory complication with poor prognosis, and tends to occur in DM patients with RP-ILD, anti-MDA5 antibody, CADM diagnosis and low CK level, especially in patients with cutaneous ulcers. Key words: Dermatomyositis; Lung diseases, interstitial; Mediastinal emphysema

Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays

BackgroundA new myositis-specific autoantibody (anti-p155) directed against transcriptional intermediary factor 1 γ (TIF1γ) has been described as a good marker of cancer-associated myositis (CAM).ObjectiveTo analyse the feasibility of detecting this...